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A B S T R A C T
Background
Colloids are widely used in the replacement of fluid volume. However doubts remain as to which colloid is best. Different colloids vary
in their molecular weight and therefore in the length of time they remain in the circulatory system. Because of this and their other
characteristics, they may differ in their safety and efficacy.
Objectives
To compare the effects of different colloid solutions in patients thought to need volume replacement.
Search strategy
We searched the Cochrane Injuries Group specialised register, the Cochrane Controlled Trials Register (2002 Issue 3), MEDLINE
(1994-2002/07), EMBASE (1974-2002 August week 1), and the National Research Register (2002 issue 3). Bibliographies of trials
retrieved were searched, and drug companies manufacturing colloids were contacted for information. The search was last updated in
September 2002.
Selection criteria
Randomised and quasi-randomised trials comparing colloid solutions in critically ill and surgical patients thought to need volume
replacement. The main outcomes measured were death, amount of whole blood transfused, and incidence of adverse reactions.
Data collection and analysis
Two authors independently extracted the data and assessed the quality of the trials.
Main results
Fifty-seven trials met the inclusion criteria, with a total of 3659 participants. Quality of allocation concealment was judged to be
adequate in 20 trials and poor or uncertain in 37.
Deaths were obtained from 36 trials. For albumin or PPF versus hydroxyethyl starch (HES) 20 trials (n=1029) reported mortality. The
pooled relative risk (RR) was 1.17 (95% CI 0.91, 1.50). For albumin or PPF versus gelatin four trials (n=542) reported mortality. The
RR was 0.99 (0.69, 1.42). For gelatin vs HES 11 trials (n=945) reported mortality, RR was 1.00 (0.78,1.28). RR was not estimable in
the albumin vs dextran, gelatin vs dextran, and HES vs dextran groups.
Thirty-six trials recorded the amount of blood transfused, however quantitative analysis was not possible due to skewness and variable
reporting. Fifteen trials recorded adverse reactions, but none occurred.
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Authors’ conclusions
From this review, there is no evidence that one colloid solution is more effective or safe than any other, although the confidence intervals
are wide and do not exclude clinically significant differences between colloids. Larger trials of fluid therapy are needed if clinically
significant differences in mortality are to be detected or excluded.
P L A I N L A N G U A G E S U M M A R Y
No strong evidence to be certain of the safety of any particular type of colloid solution for replacing blood fluids
When a person is bleeding heavily, the loss of fluid volume in their veins can lead to shock, so they need fluid resuscitation. Colloids
and crystalloids are two types of solutions used to replace lost blood fluid (plasma). They include blood and synthetic products. Both
types appear to be similarly effective at resuscitation, but one type of colloid (human albumin) was found by another Cochrane review
to increase deaths. Different colloids may have different effects. However, the review of trials found there is not enough evidence to be
sure that any particular colloid is safer than any other
B A C K G R O U N D
Colloids are used as plasma substitutes for short-term replacement
of fluid volume, while the cause of the problem is being addressed
(e.g. stopping bleeding). These solutions can be blood products
(human albumin solution, plasma protein fraction [PPF]) or syn-
thetic (modified gelatins, dextrans, etherified starches). Colloid
solutions are widely used in fluid resuscitation (Yim 1995) and
they have been recommended in a number of resuscitation guide-
lines and intensive caremanagement algorithms (Armstrong 1994;
Vermeulen 1995). Previous systematic reviews have suggested that
colloids are no more effective than crystalloids in reducing mortal-
ity (Schierhout 2000), and that albumin administration may in-
crease mortality compared to crystalloids or no fluid in a range of
uses (CIGAR 2000). Despite this, colloid solutions are still widely
used as they are thought to remain in the intravascular space for
longer than crystalloids and, therefore, be more effective in main-
taining osmotic pressure.
It is plausible that colloids may vary in their safety and effective-
ness. Different colloids vary in the length of time they remain
in the circulatory system. It may be that some low to medium
molecular weight colloids (e.g. gelatins and albumin) are more
likely to leak into the interstitial space (Traylor 1996), whereas
some larger molecular weight hydroxyethyl starches are retained
for longer (Boldt 1996). In addition it is thought that some col-
loids may effect coagulation or cause other adverse effects.
The previous review of colloids against crystalloids only allows in-
direct comparison of the different colloids. This review examines
direct comparisons of the different colloid solutions in randomised
trials to complement the earlier reviews on colloids compared
to crystalloids (Schierhout 2000) and human albumin (CIGAR
2000).
O B J E C T I V E S
To quantify the relative effects on mortality of different colloid
solutions in critically ill and surgical patients requiring volume re-
placement, by examining direct comparisons of colloid solutions.
R E S U L T S
Of the 57 trials identified 24 reportedmortality data. Information
on death was obtained from a further 12 trials by contact with the
authors. We therefore had data on death from 36 trials.
Albumin or PPF vs starch:
Twenty trials (1029 participants) reported mortality data. The
pooled relative risk was 1.17 (95% CI 0.91-1.50).
Albumin or PPF vs gelatin:
Four trials (542 participants) reported mortality but only one of
those trials had any deaths. The relative risk was 0.99 (95% CI
0.69-1.42).
Albumin or PPF vs dextran:
Three trials reported mortality and were included in the meta-
analysis. There were no deaths so relative risk was not estimable.
Gelatin vs starch:
2Colloid solutions for fluid resuscitation (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Eleven trials (945 participants) reported mortality and the pooled
relative risk was 1.00 (95% CI 0.78-1.28).
Gelatin vs dextran 70
There were two trials which reported mortality. There were no
deaths so the relative risk was not estimable.
Hydroxyethyl starch vs dextran 70:
No trials reported mortality.
Thirty-five trials recorded the amount of blood transfused. As the
data was reported in various ways, often lacking a measure of
variation, and was also skewed we did not attempt a quantitative
synthesis. This data can be seen in the “other data” table. Fifteen
trials reported the incidence of adverse or allergic reactions or
anaphylactic shock: all reported that there were no such incidents.
The effect of excluding trials judged to have inadequate (scoring
C) allocation concealment was examined in a sub-group analysis.
This made no significant difference to the results.
D I S C U S S I O N
Despite finding 57 trials we cannot make any conclusions about
the relative effectiveness of different colloid solutions. A previous
review suggested that albumin may increase mortality in critically
ill patients (CIGAR 2000), but there are too few data available
to show in direct comparisons whether the synthetic alternatives
are safer. The confidence intervals are wide and do not exclude
clinically significant differences between colloids.
Mortality was selected as the main outcome measure in this sys-
tematic review for several reasons. In the context of critical illness,
death or survival is a clinically relevant outcome that is of imme-
diate importance to patients, and data on death are reported in
many of the studies. Furthermore, one might expect that mor-
tality data would be less prone to measurement error or biased
reporting than would data on pathophysiological outcomes. The
use of a pathophysiological end point as a surrogate for an ad-
verse outcome assumes a direct relationship between the two, an
assumption that may sometimes be inappropriate. Finally, when
trials collect data on a number of physiological end-points, there
is the potential for bias due to the selective publication of end-
points showing striking treatment effects.
There was wide variation in the participants, intervention regi-
mens, and the length of follow-up. The length of follow-up is not
reported in many of the studies. Where it is reported it ranges
from a matter of hours to months, which may explain a lot of
the heterogeneity in overall event rates. The effect of these factors
was not examined in a sensitivity analysis, as there was felt to be
insufficient data to justify examining subgroups.
Many of the trials were small, and some had been done some time
ago. Although older trialswill not necessarily be of poorer quality, it
may be that treatment protocols have subsequently alteredmaking
these trials less relevant to current clinical practice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Previous reviews have failed to show any benefit of colloids over
crystalloids for volume replacement (Schierhout 2000) and sug-
gested that albumin solution may increase mortality in critically
ill patients (CIGAR 2000).
This review does not provide any evidence that one colloid is safer
than another, but does not rule out clinically significant differ-
ences.
Implications for research
Trials of fluid therapy need to be larger in order to exclude clin-
ically significant differences between colloids in patient relevant
outcomes. However, trials should probably first address the ques-
tion of whether colloids are any more effective than crystalloid
solutions.
Use of surrogate outcomes, such as physiological measurements
should be discouraged unless there is a strong relationship with
outcomes of interest to patients and relatives.
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Summary
1. Please explain, in the ’what’s new’ section, in what respects this update differs from the previous version.
2. The drug companies listed in the acknowledgments are not in alphabetic order: please do so or explain the reason for the order
shown (e.g. in order of helpfulness).
3. Fresenius is misspelt
4. In the references to included trials, please use an asterisk to identify those trials which are the main publication where there are more
than one article referring to a trial.
Author’s reply
1. The review has been marked as an update by mistake. As of September 1999 no substantial updates have been made.
2. The drug companies have been re-ordered alphabetically.
3. The spelling of Fresenius is corrected.
4. The primary reference has been marked with an asterisk.
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